Undisclosed TIGIT ETB / Molecular Templates - LARVOL DELTA

Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice (SITC 2022) - "6 Here, we demonstrate the efficacy and pharmacodynamic (PD) effects of TIGIT ETB in a hTIGIT/PD-1 expressing humanized mouse model...Conclusions These data demonstrate that targeting TIGIT using our Engineered Toxin Body platform promotes tumor regression through elimination of TIGIT/PD-1 co-expressing immune cells within the TME. Our data supports using ETB as a monotherapy to target TIGIT and represents a wholly novel approach for modulating TIGIT within the TME."

Preclinical • Tumor microenvironment • Oncology • Solid Tumor • CD4 • PVR • TIGIT